Lanean...
Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal
INTRODUCTION: Current FDA-approved smoking cessation pharmacotherapies have limited efficacy and are associated with high rates of relapse. Therefore, there is a clear need to develop novel antismoking medications. Nicotine withdrawal is associated with cognitive impairments that predict smoking rel...
Gorde:
| Argitaratua izan da: | Expert Opin Drug Discov |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4287224/ https://ncbi.nlm.nih.gov/pubmed/24707983 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/17460441.2014.908180 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|